|Security||CTSO / Cytosorbents Corp (23283X206)|
|Industry||Surgical and Medical Instruments and Apparatus|
|Common Shares Outstanding||29,471,343 shares (as of 2017-12-31)|
Stock Insider Trading (from SEC Form 4)
Cytosorbents Corp insider trades are listed in the following table, followed by a table containing the full transaction history. Insiders are officers, directors, or significant investors in a company. In general, it is generally illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4.
CTSO / Cytosorbents Corp insiders include BARTLETT ROBERT HAWES, Capponi Vincent, Jones Edward Raymond, Gunton James T., NJTC INVESTMENT FUND, LP, and BLOCH KATHLEEN P., Kraus Al, Mortensen Eric R. BATOR MICHAEL G., Sobel Alan D., Chan Phillip P., .
BLOCH KATHLEEN P.
Sobel Alan D.
BATOR MICHAEL G.
Jones Edward Raymond
Mortensen Eric R.
Chan Phillip P.
BARTLETT ROBERT HAWES
NJTC INVESTMENT FUND, LP
Gunton James T.
Click the link icon to see the full transaction history. Transactions reported as part of a 10b-5 automatic trading plan will have an X in the column marked 10b-5.
|4||BLOCH KATHLEEN P.||S||X||D||8.75||-12,400||262,304||2,295,160|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||12,400||274,704|
|4||BLOCH KATHLEEN P.||S||X||D||9.00||-12,400||262,304||2,360,736|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||12,400||274,704|
|4||BLOCH KATHLEEN P.||S||X||D||8.50||-10,000||262,304||2,229,584|
|4||BLOCH KATHLEEN P.||M||X||D||2.90||10,000||272,304|
|4||Jones Edward Raymond||A||D||3,300||71,800|
|4||BATOR MICHAEL G.||A||D||3,300||73,800|
|4||Sobel Alan D.||A||D||3,300||69,300|
|4||BLOCH KATHLEEN P.||S||X||D||8.25||-120||262,304||2,164,008|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||120||262,424|
|4||BLOCH KATHLEEN P.||S||X||D||8.00||-10,000||267,870||2,142,960|
|4||BLOCH KATHLEEN P.||M||X||D||2.90||10,000||277,870|
|4||Mortensen Eric R.||A||D||20,000||36,500|
|4||BLOCH KATHLEEN P.||A||D||8,800||266,870|
|4||Chan Phillip P.||A||D||10,300||440,713|
|4||BLOCH KATHLEEN P.||S||X||D||8.25||-11,176||259,070||2,137,328|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||11,176||270,246|
|4||BLOCH KATHLEEN P.||S||X||D||8.25||-1,104||259,070||2,137,328|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||1,104||260,174|
|4||Mortensen Eric R.||A||D||14,000||16,500|
|4||Chan Phillip P.||A||D||43,000||430,413|
|4||BLOCH KATHLEEN P.||A||D||34,700||259,070|
|4||BLOCH KATHLEEN P.||S||X||D||7.75||-12,400||237,638||1,841,694|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||12,400||250,038|
|4||BLOCH KATHLEEN P.||S||X||D||7.50||-10,000||237,638||1,782,285|
|4||BLOCH KATHLEEN P.||S||X||D||7.25||-12,400||247,638||1,795,376|
|4||BLOCH KATHLEEN P.||S||X||D||7.15||-10,000||260,038||1,859,272|
|4||BLOCH KATHLEEN P.||M||X||D||4.69||12,400||270,038|
|4||BLOCH KATHLEEN P.||M||X||D||2.90||20,000||257,638|
|4||Mortensen Eric R.||P||D||4.0398||2,500||2,500||10,100|
|4||BATOR MICHAEL G.||P||D||4.12||1,500||70,500||290,460|
|4||Jones Edward Raymond||P||D||3.9995||2,000||68,500||273,966|
- Open market or private purchase of non-derivative or derivative security
- Open market or private sale of non-derivative or derivative security
- Grant, award, or other acquisition of securities from the company (such as an option)
- Conversion of derivative
- Sale or transfer of securities back to the company
- Payment of exercise price or tax liability using portion of securities received from the company
- Gift of securities by or to the insider
- Equity swaps and similar hedging transactions
- Exercise or conversion of derivative security received from the company (such as an option)
- A transaction voluntarily reported on Form 4
- Other (accompanied by a footnote describing the transaction)
14h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
14h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
2018-05-21 - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...
Related News Stories
Good afternoon and welcome to the Cytosorbents' First Quarter 2018 financial and operating results conference call. At this time, all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded at the Company's request.
Both the overall market and the main biotech indices managed a slight gain Thursday as new proposed tariffs were better than the worse case scenario. (93-0)
The following slide deck was published by Cytosorbents Corp in conjunction with their 2017 Q4 earnings call.
Good afternoon and welcome to the CytoSorbents 2017 Financial and Operating Results Conference Call. At this time all participants are in a listen-only mode. Following the formal remarks, we will open the call for your questions. Please be advised that the call will be recorded as the Company's request. At this time, I'd like to turn the call over to our moderator, Jeremy Feffer. Please go ahead, Mr.
* CYTOSORBENTS CORP - BIOCON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE CYTOSORB IN MALAYSIA, WHERE CYTOSORB IS ALREADY REGISTERED
as of ET